Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs.
AffiliationClinical and Experimental Pharmacology, Paterson Institute for Cancer Research, University of Manchester, Wilmslow Road, Manchester M20 4BX, England. email@example.com
MetadataShow full item record
AbstractClinical development of new anticancer drugs can be compromised by a lack of qualified biomarkers. An indispensable component to successful biomarker qualification is assay validation, which is also a regulatory requirement. In order to foster flexible yet rigorous biomarker method validation, the fit-for-purpose approach has recently been developed. This minireview focuses on many of the basic issues surrounding validation of biomarker assays utilised in clinical trials. It also provides an overview on strategies to validate each of the five categories that define the majority of biomarker assays.
CitationFit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs. 2010, 103 (9):1313-7 Br J Cancer
JournalBritish Journal of Cancer
- Fit-for-purpose biomarker method validation in anticancer drug development.
- Authors: Cummings J, Ward TH, Dive C
- Issue date: 2010 Oct
- Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs.
- Authors: Brookes K, Cummings J, Backen A, Greystoke A, Ward T, Jayson GC, Dive C
- Issue date: 2010 May 11
- Biomarker method validation in anticancer drug development.
- Authors: Cummings J, Ward TH, Greystoke A, Ranson M, Dive C
- Issue date: 2008 Feb
- Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
- Authors: Lee JW, Figeys D, Vasilescu J
- Issue date: 2007
- Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
- Authors: Tan DS, Thomas GV, Garrett MD, Banerji U, de Bono JS, Kaye SB, Workman P
- Issue date: 2009 Sep-Oct